Form 4: Inmune Bio Director James Kelly Ganjei Acquires 32,500 Stock Options

Director James Kelly Ganjei of Inmune Bio, Inc. was granted 32,500 stock options on December 5, 2024, which will vest on December 5, 2026.

Summary

• James Kelly Ganjei, a director at Inmune Bio, Inc., was granted 32,500 stock options on December 5, 2024.
• The options have an exercise price of $5.05.
• These options were granted under the 2021 Stock Incentive Plan.
• The options will fully vest and become exercisable on December 5, 2026, which is two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting period of two years encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotechnology sector.
• The vesting period of two years is typical for such grants, designed to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to work towards increasing the company's value.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, equity, Inmune Bio, director, vesting